Shared pathways: Death receptors and cytotoxic drugs in cancer therapy

Pathology and Oncology Research

Volumn 7, Issue 2, 2001, Pages 95-106

  Petak, I ^a   Houghton, J A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Apoptosis; Death receptor; Drug; Fas; p53; Tumor

Indexed keywords

CASPASE 8; CYTOTOXIC AGENT; FAS LIGAND; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER THERAPY; DNA DAMAGE; ENZYME ACTIVATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 0034899716     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03032574     Document Type: Review

References (148)

1. Death receptors: Signaling and modulation
2. Apoptosis mediated by the TNF-related cytokine and receptor families
3. Regulation of tumor necrosis factor-alpha processing by a metalloproteinase inhibitor
4. Downregulation of Fas ligand by shedding
5. Metalloproteinase-mediated release of human Fas ligand
6. Apoptosis control by death and decoy receptors
7. The Fas death factor
8. Gene transfer of Fas ligand induces tumor regression in vivo
9. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
10. Expression of Apo-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium
11. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
12. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
13. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain
14. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
15. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO1 and TNF receptor-induced cell death
16. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)
17. FLICE a novel FADD-homologous ICE/CED-3-like protease is recruited to the CD95 (Fas/Apo-l) death-inducing signaling complex
18. Inhibition of death receptor signals by cellular FLIP
19. The role of c-FLIP in modulation of CD95-induced apoptosis
20. Two CD95 (APO-1/Fas) signaling pathways
21. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
22. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c
23. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
24. TRAIL/Apo-2-ligand-induced apoptosis in human T cells
25. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
26. TRAIL: A molecule with multiple receptors and control mechanisms
27. Differential localization and regulation of death and decoy receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in human melanoma cells
28. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
29. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
30. Identification and characterization of a new member of the TNF family that induces apoptosis
31. The receptor for the cytotoxic ligand TRAIL
32. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
33. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
34. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
35. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
36. A novel receptor for Apo2L/TRAIL contains a truncated death domain
37. Expression of TRAIL and its receptors in human brain tumors
38. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
39. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
40. Safety and antitumor activity of recombinant soluble Apo2 ligand
41. APO2 ligand: A novel weapon against malignant glioma?
42. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB
43. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
44. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
45. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
46. Apoptosis induced by anticancer drugs
47. Apoptosis provides new targets for chemotherapy
48. Apoptosis and cancer drug targeting
49. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
50. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
51. An ICE-like protease is a common mediator of apoptosis induced by diverse stimuli in human monocytic THP. 1 cells
52. BCNU is a caspase-mediated inhibitor of drug-induced apoptosis
53. Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells
54. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized
55. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells
56. Etoposide at different concentrations may open different apoptotic pathways in thymocytes
57. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival
58. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1
59. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression
60. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
61. The CD95 (APO1-Fas) system mediates drug-induced apoptosis in neuroblastoma cells
62. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD9J) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells
63. Comparison of Apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not demendent on Fas/Fas ligand interactions
64. Antileukemic drugs increase death receptor 5 levels and enhance apo-2L-induced apoptosis of human acute leukemia cells
65. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
66. Chemotherapy augmants TRAIL-induced apoptosis in breast cell lines
67. Fas ligand mediates activation-induced cell death in human T lymphocytes
68. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
69. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells
70. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis
71. Thymineless death in colon carcinoma cells is mediated via Fas signaling
72. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells
73. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs
74. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system
75. Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells
76. P53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer agents
77. P53-dependence of Fas induction amd acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines
78. Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells
79. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis
80. Activation of the Fas pathway independently of fas ligand during apoptosis induced by camptothecin in p53 mutant colon carcinoma cells
81. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3
82. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction
83. Caspase-8 activation and Bid cleavage contribute to MCF7 cellular execution in a caspase3-dependent manner during staurosporine-mediated apoptosis
84. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460
85. Cisplatin (CDDP) sensitizes human osteosarcoma cells to Fas/CD95-mediated apoptosis by downregulating FLIP-L expression
86. Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism
87. Regulation of CD95 expression and CD95-mediated cell death by interferon-gamma in acute lymphoblastic leukemia with chromosomal translocation t(4;11)
88. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
89. TRAIL death pathway expression and induction in thyroid follicular cells
90. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma radiation
91. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases)
92. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and -radiation downstream from caspase-8 activation
93. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
94. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin
95. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells
96. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression
97. A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis
98. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells
99. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo
100. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
101. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
102. JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNT-alpha
103. Induction of CD95 ligand and apoptosis by doxombicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells
104. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis
105. Daunorubicin activates NF-κB and induces κB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells
106. Rel/NF-kappaB/IkappaB story
107. The NF-kappaB and I kappaB proteins: New discoveries and insights
108. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway
109. The regulation of AP-1 activity by mitogen-activated protein kinases
110. The stress-activated protein kinase subfamily of c-Jun kinases
111. Differential activation of ERK and INK mitogen-activated protein kinases by Raf-1 and MEKK
112. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
113. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and radiation
114. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents
115. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents
116. Adriamycin activates c-jun N-terminal kinase in human leukemia cells: A relevance to apoptosis
117. c-Jun NH2-terminal kinase-mediated activation of interleukin-lβ converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis
118. Cisplatin induces a persistent activation of JNK that is related to cell death
119. Cutting edge: p21-activated kinase (PAK) is required for Fas-induced JNK activation in Jurkat cells
120. Three distinct signaling responses by murine fibroblasts to genotoxic stress
121. A caspase-activated Dnase that degrades DNA during apoptosis, and its inhibitor ICAD
122. Activation of the IκBκ kinase complex by MEKK1, a kinase of the JNK pathway
123. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor κB (NF-κB) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes
124. Topoisomerase poisons activate the transcription factor NF-κB in ACH-2 and CEM cells
125. Activation of the transcription factor kappaB in human KG-1 myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine
126. Sphingomyelin breakdown and cell fate
127. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals
128. Functions of ceramide in coordinating cellular responses to stress
129. Mechanisms of ceramide-mediated apoptosis
130. Signal transduction of stress via ceramide
131. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
132. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling
133. Signal transduction through lipid second messengers
134. The long-chain sphingold base of sphingolipids is acylated at the cytosolic surface of the endoplasmic reticulum in rat liver
135. Fatty acyl-Co A: Sphingosine acyltransferase in bovine brain mitochondria: Its solubilization and reconstitution onto the membrane lipid liposomes
136. Distinct adapter proteins mediate acid versus neutral sphingomyelinase activation through the p55 receptor for tumor necrosis factor
137. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase
138. Requirement of FADD for tumor necrosis factor-induced activation of acid sphingomyelinase
139. Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells
140. Apafl (CED-4 homolog) regulates programmed cell death in mammalian development
141. The central executioner of apoptosis: Multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis
142. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis
143. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis
144. Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells
145. p53-dependent ceramide response to genotoxic stress
146. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells
147. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
148. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate